Molecular genetic analysis has allowed the elucidation of the etiology of many single-gene, neurodegenerative syndromes. However, as yet, it has had little direct impact on our understanding of the etiology in cases with more complex modes of inheritance. With the completion of the sequence of the human genome, it should be possible to start to attack these more complex problems. In this article, we review the genetic methods that may be used to dissect the etiologies of these diseases and outline what types of clinical samples will be needed for this quest.
INTRODUCTION
With the beginning of the new millennium, we are entering the postgenome era. Within the next year, the vast majority of human genes will have been sequenced and their sequences will be available on the World-Wide Web. In the past 10 years, the application of molecular genetics has led to the unraveling of the etiologies of most of the single-gene disorders that lead to neurodegenerative disease, but has barely begun to allow the dissection of the more complex genetics of most neurodegenerative diseases which do not show simple patterns of inheritance. The only genes which have been unambiguously identified as risk factors for non-Mendelian disorders are the prion gene in iatrogenic and idiopathic Creuzfeldt-Jakob disease (Collinge et al., 1991; Palmer et al., 1991) , the apolipoprotein E gene in Alzheimer's disease (Corder et al., 1993) , and the tau gene in progressive supranuclear palsy (Baker et al., 1999) . In the cases of both the prion and tau genes, there were good genetic or pathologic reasons for suspecting, a priori, their involvement in disease etiology (Hsiao et al., 1989; Flament et al., 1991) ; thus, apolipoprotein E is the only neurodegenerative risk factor gene found, in part, through positional genetic analysis (Pericak-Vance et al., 1990) It is to be expected that over the next period, the application of molecular genetic techniques will promote the dissection of the etiologies of non-Mendelian neurodegenerative diseases in general; however, the problems of identifying risk factor loci for diseases with complex modes of inheritance and in particular oligogenic (10 genes) and polygenic (Ͼ10 genes) disease are formidable. Given the huge socioeconomic impact of some of the disorders of this nature such as Parkinson's disease and Alzheimer's disease, it is of paramount importance to design a viable strategy for the delineation of genetic predisposition in complex traits. The purpose of this review is to outline how progress in molecular genetic technologies can be used to solve these difficult problems and also to discuss the types of sample series needed to facilitate this endeavor.
THE INFRASTRUCTURE PROVIDED BY THE HUMAN GENOME PROJECT
The Human Genome Project is providing infrastructure in several ways:
(1) Most obviously by the sequencing of human cDNAs and cDNA fragments. This endeavor is the one Neurobiology of Disease 7, 65-69 (2000) nbdi.2000.0291, available online at http://www.idealibrary.com on
